Ulcerative Colitis Patient-Reported Outcomes (UC-PRO)

Expand the efficacy profile of your product with patient-reported outcomes in six critical measures

Gain critical insight into treatment efficacy in adult ulcerative colitis (UC) patients. The UC-PRO is a self-administered patient-reported outcome (PRO) measure developed in accordance with the U.S. Food and Drug Administration (FDA) Guidelines for Content Validity and Instrument Performance. This measure is intended for use in clinical trials evaluating treatment efficacy in adult patients (at least 18 years old) with moderate to severe UC treated in an outpatient setting. 

The UC-PRO is conceptually designed as a collection of separate and distinct modules that assess the signs, symptoms and impacts of UC:

The UC-PRO Signs and Symptoms (CD-PRO/SS) is a nine-item daily diary designed to quantify the effects of treatment on patient-reported signs and symptoms of UC. The UC-PRO/SS includes two scales — Bowel Signs and Symptoms (six items) and Functional Symptoms (three items). Each scale is scored separately; there is no total score for the CD-PRO/SS. 

This measure uses a 24-hour recall and was designed and tested as an e-diary on a handheld device. Electronic administration is strongly recommended. The paper format was used in the cognitive interviewing phase of instrument development only and is available upon request. 

The UC-PRO/SS measure is currently under review by the FDA as part of the FDA Qualification Program (DDT COA 000040). In addition, international health authority qualification advice was sought by the European Medicines Agency (EMA) and a letter of support was received. 

It is the user’s responsibility to select and contract with the ePRO vendor and ensure that the proper licenses are in place. 

The Systemic Symptoms measure includes five items, scored as a single scale, to address the presence and severity of systemic symptoms, including pain, fatigue, lack of appetite, weakness and thirst. 

This measure uses a 24-hour recall and was designed and tested as an e-diary on a handheld device. Electronic administration is strongly recommended. The paper format was used in the cognitive interviewing phase of instrument development only and is available upon request. 

It is the user’s responsibility to select and contract with the ePRO vendor and ensure that the proper licenses are in place. 

The Coping Strategies measure includes six items, scored as a single score, to address coping strategies such as scheduling activities, eating to control bowel movements, avoiding foods, not going out unless toilets are nearby, carrying a change of clothes and staying home due to UC.  

This measure uses a 24-hour recall and was designed and tested as an e-diary on a handheld device. Electronic administration is strongly recommended. The paper format was used only in the cognitive interviewing phase of instrument development and is available upon request. 

It is the user’s responsibility to select and contract with the ePRO vendor and ensure that the proper licenses are in place. 

The Daily Life Impact measure includes nine items, scored as a single scale, to address interference with work /school, chores, activities for enjoyment, sleep, ability to concentrate, leaving home, ability to travel, sex and planning activities due to UC. 

This measure uses a one-week recall and was designed and tested in a paper format. The ePRO format (i.e., screenshots) is available upon request.  

The Emotional Impact measure includes eight items, scored as a single scale, to address feeling alone, embarrassed, worried, scared, having no control in life, angry, frustrated and depressed due to UC. 

This measure uses a one-week recall and was designed and tested in a paper format. The ePRO format (i.e., screenshots) is available upon request.  

clinical trial doctor with tablet

Licensing information

As the contracted agency approved by the UC-PRO copyright holder (Amgen Inc., Genentech Inc., and the University of Michigan) to license and distribute the UC-PRO, we uphold our responsibility to protect the integrity of the UC-PRO as it is distributed for use, including development of translations.

A user agreement is required for all requests to use the UC-PRO in research, and use is granted for a single study only. Fees for licensure vary depending on the type of user making the request and the nature of the research. To inquire about terms and fees for licensure to use the UC-PRO, please choose the appropriate affiliation below to submit your interest, and you will be contacted by a COA expert with information relevant to your needs.

Translations available

CountryLanguageSigns & symptomsSystemic symptomsCoping strategiesDaily life impactEmotional impact
Argentina Spanish 
Australia English 
Austria German 
Belarus Russian    
Belgium Dutch 
Belgium English 
Belgium French 
Bosnia & Herzegovina Bosnian     
Bosnia & Herzegovina Croatian     
Bosnia & Herzegovina Serbian-Latin     
Brazil Portuguese 
Bulgaria Bulgarian 
Canada English 
Canada French 
Chile Spanish     
China Chinese-Simplified     
Colombia Spanish     
Croatia Croatian     
Czech Republic Czech 
Denmark Danish 
Egypt Arabic     
Estonia Estonian     
Estonia Russian     
Finland Finnish 
Finland Swedish 
France French 
Georgia Georgian    
Georgia Russian     
Germany German 
Greece Greek 
Hong Kong Chinese-Traditional     
Hungary Hungarian 
India Bengali     
India English     
India Gujarati     
India Hindi     
India Kannada     
India Malayalam     
India Marathi     
India Odia     
India Punjabi     
India Tamil     
India Telugu     
India Urdu     
Israel Arabic 
Israel Hebrew 
Israel Russian 
Italy Italian 
Japan Japanese 
Jordan Arabic     
Latvia Latvian 
Latvia Russian 
Lebanon Arabic     
Lebanon French     
Lithuania Lithuanian     
Lithuania Russian 
Malaysia Chinese-Simplified     
Malaysia English     
Malaysia Malay     
Malaysia Tamil     
Mexico Spanish 
Moldova Romanian     
Moldova Russian     
Netherlands Dutch 
New Zealand English     
Norway Norwegian     
Philippines Cebuano     
Philippines English     
Philippines Hiligaynon     
Philippines Tagalog     
Poland Polish 
Portugal Portuguese    
Puerto Rico Spanish     
Romania Romanian 
Russia Russian 
Saudi Arabia Arabic     
Serbia Serbian-Cyrillic     
Serbia Serbian-Latin 
Singapore Chinese-Simplified     
Singapore Malay     
Slovakia Slovak 
Slovenia Slovene 
South Africa Afrikaans    
South Africa English    
South Africa Sesotho     
South Africa Xhosa     
South Africa Zulu     
South Korea Korean 
Spain Catalan 
Spain Galician 
Spain Spanish 
Sweden Swedish 
Switzerland French 
Switzerland German 
Switzerland Italian 
Taiwan Chinese-Traditional 
Thailand Thai     
Turkey Turkish 
UK English 
Ukraine Russian 
Ukraine Ukrainian 
USA Spanish 

While the list of available translations is extensive, the process for any additional translations needed is outlined below:

  • We must conduct all translation work using our preferred vendors who have a history with this COA
  • Standardized methods for COA translation are followed and certification letters are provided
  • Please provide your language needs on your submission form, and you will be provided with a cost estimate and timeline with our reply to the details of your project

Available resources

Higgins PDR, Harding G, Revicki DA, Globe G, Patrick DL, et al. Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-PRO/SS) diary. JPRO. May 2018;2:26.

Pulley J, Galloway D, Devine J, Oh YS, Petrek H, Kadva A, Mastui A. Minimal Clinically Important Difference (MCID) for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool. Poster presented at: 16th Congress of the European Crohn’s and Colitis Organisation (ECCO) Congress; July 2-3 & 8-10, 2021; Virtual.

Higgins PDR, DeBusk K, Pulley J, Scalori A, Oh YS, Matsui A. Responder Definitions for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool Using Patients With Ulcerative Colitis Treated With Etrolizumab. Poster presented at: Digestive Disease Week; May 18-21, 2019; San Diego, CA.

Higgins PDR, DeBusk K, Pulley J, Scalori A, Oh YS, Matsui A. Responder Definitions for the Ulcerative Colitis Patient-Reported Outcomes Signs and Symptoms (UC-PRO/SS) Tool Using Patients With Ulcerative Colitis Treated With Etrolizumab. Poster presented at: 14th Congress of European Crohn’s and Colitis Organisation; March 6–9, 2019; Copenhagen, Denmark.

Higgins PD, Harding G, Patrick DL, Revicki D, Chen WH, Globe G, Viswanathan HN, Fitzgerald K, Trease S, Borie D, Ortmeier BG, Leidy NK. Psychometric Evaluation of the Coping, Daily Life Impact, and Emotional Impact Modules of the Ulcerative Colitis Patient-Reported Outcomes (UC-PRO) Measure. Poster presented at: UEG Week 2014; October 18–22, 2014; Vienna, Austria.

Higgins PD, Harding G, Patrick DL, Revicki D, Chen WH, Globe G, Viswanathan HN, Fitzgerald K, Trease S, Borie D, Ortmeier BG, Leidy NK. Psychometric Evaluation of the Signs and Symptoms Modules of the Ulcerative Colitis Patient-Reported Outcomes Measure (UC-PRO/SS). Poster presented at: UEG Week 2014; October 18–22, 2014; Vienna, Austria.

Higgins PDR, Harding G, Patrick DL, Revicki D, Globe G, Viswanathan HN, Trease S, Fitzgerald K, Borie D, Ortmeier BG, Leidy N. Development of the Ulcerative Colitis Patient-Reported Outcomes (UC-PRO) Questionnaire. Poster presented at: Digestive Disease Week 2013; May 18–21, 2013; Orlando, FL.

The CD-PRO User Manual provides an overview of the development and validation studies for the five modules and describes the scoring method.

Interested in more information about our COA offerings? Contact us.